´ÙÁß ¾Ï Á¶±â ¹ß°ß(MCED) ½ÃÀå : Á¦Ç° À¯Çüº°, ±â¼úº°, ÃÖÁ¾ »ç¿ëÀÚº°, ±¹°¡º°, Áö¿ªº° - »ê¾÷ ºÐ¼®, ½ÃÀå ±Ô¸ð, ½ÃÀå Á¡À¯À² ¹× Àü¸Á(2023-2030³â)
Multi-Cancer Early Detection Market, By Product Type, By Technology, By End User, By Country, and By Region - Industry Analysis, Market Size, Market Share & Forecast from 2023-2030
»óǰÄÚµå : 1401799
¸®¼­Ä¡»ç : AnalystView Market Insights
¹ßÇàÀÏ : 2023³â 12¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 311 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 3,250 £Ü 4,702,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠺Ұ¡´ÉÇϸç, ÅØ½ºÆ®ÀÇ Copy&Pasteµµ ºÒ°¡´ÉÇÕ´Ï´Ù.
US $ 4,650 £Ü 6,728,000
PDF (5 User License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ »ç¾÷Àå¿¡¼­ 5¸í±îÁö ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 5,650 £Ü 8,174,000
PDF & Excel (Enterprise User License) help
PDF & Excel º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ ³» ¸ðµç »ç¿ëÀÚ°¡ »ç¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. ÅØ½ºÆ®ÀÇ Copy&Paste °¡´ÉÇÕ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


¤± Add-on °¡´É: °í°´ÀÇ ¿äû¿¡ µû¶ó ÀÏÁ¤ÇÑ ¹üÀ§ ³»¿¡¼­ CustomizationÀÌ °¡´ÉÇÕ´Ï´Ù. ÀÚ¼¼ÇÑ »çÇ×Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

Çѱ۸ñÂ÷

º¸°í¼­ÀÇ ÁÖ¿ä ³»¿ë

´ÙÁß ¾Ï Á¶±â ¹ß°ß(MCED) ½ÃÀå ½ÃÀå ±Ô¸ð´Â 2022³â 8¾ï 8,000¸¸ ´Þ·¯·Î Æò°¡µÇ¾ú°í, 2023³âºÎÅÍ 2030³â±îÁö 16.2%ÀÇ ¿¬Æò±Õ º¹ÇÕ ¼ºÀå·ü(CAGR)·Î È®´ëµÉ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

MCED(´Ù¹ß¼º ¾Ï Á¶±â ¹ß°ß) ½ÃÀå - ½ÃÀå ¿ªÇÐ

¾Ï ¹ßº´·ü Áõ°¡¿Í °¢±¹ Á¤ºÎÀÇ ¾Ï Á¶±â ¹ß°ß¿¡ ´ëÇÑ °­Á¶°¡ ½ÃÀå ¼ö¿ä¸¦ ÃËÁøÇÕ´Ï´Ù.

MCED(Multiple Cancer Early Detection) ½ÃÀåÀº ¾Ï ¹ßº´·ü Áõ°¡, Á¤ºÎÀÇ ¾Ï Á¶±â ¹ß°ß¿¡ ´ëÇÑ °ü½É Áõ°¡ µî ´Ù¾çÇÑ ¿äÀÎÀ¸·Î ÀÎÇØ ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹»óµÇ¸ç, 2020³â ¼¼°èº¸°Ç±â±¸(WHO)¿¡ µû¸£¸é ¾ÏÀº Àü ¼¼°è »ç¸Á ¿øÀÎ 1À§·Î ¾à 1,000¸¸ ¸íÀÌ »ç¸ÁÇÏ°í »ç¸ÁÀÚ 6¸í Áß 1¸íÀÌ ¾ÏÀ¸·Î »ç¸ÁÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. »ç¸ÁÀÚ 6¸í Áß 1¸íÀ» Â÷ÁöÇÕ´Ï´Ù. Èí¿¬, °íüÁú·®Áö¼ö, À½ÁÖ, ºñ¸¸, ÄÝ·¹½ºÅ×·Ñ ¼öÄ¡ »ó½Â µîÀÇ ¿äÀÎÀÌ ¾Ï °ü·Ã »ç¸Á ¿øÀÎÀÇ ¾à 1/3À» Â÷ÁöÇÕ´Ï´Ù. ȯÀÚÀÇ »ýÁ¸À²À» ³ôÀ̰í Ä¡·á ºñ¿ëÀ» ÁÙÀ̱â À§ÇØ ¾Ï Á¶±â ¹ß°ßÀÇ Á߿伺¿¡ ´ëÇÑ ÀνÄÀÌ ³ô¾ÆÁü¿¡ µû¶ó ÀÌ ½ÃÀåÀº Å« ±âȸ¸¦ Á¦°øÇÕ´Ï´Ù. È¿À²ÀûÀÎ ¾Ï Á¶±â ¹ß°ß ¹æ¹ý¿¡ ´ëÇÑ ¼ö¿ä´Â È¿À²ÀûÀÎ Áúº´ °ü¸®¸¦ ÃËÁøÇÏ°í »ç¸Á·üÀ» ³·Ã߱⠶§¹®¿¡ Àüü ½ÃÀåÀÇ ¼ºÀåÀ» °¡¼ÓÇÒ °ÍÀÔ´Ï´Ù.

MCED(´Ù¹ß¼º ¾Ï Á¶±â ¹ß°ß) ½ÃÀå - ÁÖ¿ä ÀλçÀÌÆ®

´ç»çÀÇ ¸®¼­Ä¡ ¾Ö³Î¸®½ºÆ®ÀÇ ºÐ¼®¿¡ µû¸£¸é, ¼¼°è ½ÃÀåÀº ¿¹Ãø ±â°£(2023-2030³â) µ¿¾È ¾à 16.2%ÀÇ ¿¬Æò±Õ º¹ÇÕ ¼ºÀå·ü(CAGR)·Î ¸Å³â ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

Á¦Ç° À¯Çüº°·Î´Â À¯ÀüÀÚ ÆÐ³Î, LDT, ±âŸ°¡ 2022³â °¡Àå Å« ½ÃÀå Á¡À¯À²À» Â÷ÁöÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

ÃÖÁ¾ »ç¿ëÀÚ ¼¼ºÐÈ­¿¡¼­´Â º´¿øÀÌ 2022³â ÁÖ¿ä À¯ÇüÀ¸·Î ³ªÅ¸³µ½À´Ï´Ù.

Áö¿ªº°·Î´Â ºÏ¹Ì°¡ 2022³â¿¡ ¼öÀÍÀ» âÃâÇÏ´Â ÁÖ¿ä ½ÃÀåÀ¸·Î ²ÅÇû½À´Ï´Ù.

MCED(´Ù¹ß¼º ¾Ï Á¶±â ¹ß°ß) ½ÃÀå - ¼¼ºÐÈ­ ºÐ¼® :

¼¼°è ´ÙÁß ¾Ï Á¶±â ¹ß°ß(MCED) ½ÃÀå ½ÃÀåÀº Á¦Ç° À¯Çü, ±â¼ú, ÃÖÁ¾ »ç¿ëÀÚ ¹× Áö¿ª¿¡ µû¶ó ¼¼ºÐÈ­µË´Ï´Ù.

Á¦Ç° À¯Çü¿¡ µû¶ó ½ÃÀåÀº ¾×ü »ý°Ë°ú À¯ÀüÀÚ ÆÐ³Î, LDT, ±âŸ·Î ±¸ºÐµÇ¸ç, 2022³â¿¡´Â À¯ÀüÀÚ ÆÐ³Î, LDT, ±âŸ ºÎ¹®ÀÌ ¼öÀÍÀÇ °¡Àå Å« ºÎºÐÀ» Â÷ÁöÇÒ °ÍÀ¸·Î ¿¹»óµÇ´Âµ¥, ÀÌ´Â ÁÖ·Î ¿©·¯ À¯ÇüÀÇ ¾Ï¿¡ ´ëÇÑ °Ë»ç Á¦°ø¿¡ ±âÀÎÇÑ °ÍÀ¸·Î ºÐ¼®µË´Ï´Ù. À¯ÀüÀÚ ÆÐ³ÎÀº ƯÈ÷ À¯Àü¼º ¾ÏÀÇ ½Äº°À» ¸ñÇ¥·Î Çϰí ÀÖÀ¸¸ç, À¯Àü¼º ¾Ï¿¡ ´ëÇÑ ÀνÄÀÌ ³ô¾ÆÁü¿¡ µû¶ó ¾ÏÀ» Á¶±â¿¡ ¹ß°ßÇÒ ¼ö ÀÖ´Â À¯ÀüÀÚ °Ë»ç¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡ÇÏ¿© ȯÀÚÀÇ »ýÁ¸À²À» ³ôÀ̰í ÀÖ½À´Ï´Ù.

½ÃÀåÀº ÃÖÁ¾ »ç¿ëÀÚ¿¡ µû¶ó º´¿ø, Áø´Ü ½ÇÇè½Ç ¹× ±âŸ ¼¼ °¡Áö ¹üÁÖ·Î ºÐ·ùµË´Ï´Ù. º´¿ø ºÎ¹®Àº 2022³â Å« ¼öÀÍ Á¡À¯À²À» È®º¸Çϸç Àüü ½ÃÀå¿¡¼­ Áö¹èÀûÀÎ ¼¼·ÂÀ¸·Î ºÎ»óÇß½À´Ï´Ù. ÀÌ·¯ÇÑ ¿ìÀ§´Â ´Ù¾çÇÑ Áõ»óÀÇ Áø´Ü°ú Ä¡·á¿¡ Á¾»çÇÏ´Â Àü¹®ÀÇ¿Í ÀÇ·áÁøÀÇ Á¸Àç¿¡ ±âÀÎÇÕ´Ï´Ù. º´¿øÀº ƯÁ¤ Áúº´°ú Àå¾Ö¿¡ ´ëÇØ °³ÀÎÀ» ±³À°Çϰí ÀνÄÀ» ³ôÀÌ´Â Ç÷§Æû ¿ªÇÒÀ» Çϰí ÀÖÀ¸¸ç, MCED(´Ù¹ß¼º ¾Ï Á¶±â ¹ß°ß)´Â ´ëÁßÀÇ ÀÎÁöµµ°¡ ³·Àº ½Å±â¼úÀ̱⠶§¹®¿¡ º´¿øÀº Áß¿äÇÑ ¿ªÇÒÀ» Çϰí ÀÖ½À´Ï´Ù. º´¿øÀº ¹«Áõ»ó ȯÀÚÀÇ ¿©·¯ ¾ÏÁ¾¿¡ ´ëÇÑ °Ë»ç¸¦ ¿ëÀÌÇÏ°Ô Çϰí ÈÄ¼Ó Ä¡·á ÀýÂ÷¸¦ °£¼ÒÈ­ÇÕ´Ï´Ù.

MCED(´Ù¹ß¼º ¾Ï Á¶±â ¹ß°ß) ½ÃÀå - Áö¸®Àû ÀλçÀÌÆ®

Áö¿ªÀûÀ¸·Î ÀÌ ½ÃÀåÀº ºÏ¹Ì, ¶óƾ¾Æ¸Þ¸®Ä«, À¯·´, ¾Æ½Ã¾ÆÅÂÆò¾ç, Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«·Î ³ª´¹´Ï´Ù. ÀÌ Áö¿ªÀº ºñÁî´Ï½º¸¦ °¡Á® ¿À´Â ±¹°¡¿¡ µû¶ó ´õ ¼¼ºÐÈ­µË´Ï´Ù.

MCED(´Ù¹ß¼º¾Ï Á¶±â¹ß°ß) ½ÃÀå - °æÀï»óȲ:

´ÙÁß¾Ï Á¶±âÁø´Ü(MCED) ½ÃÀåÀº ¾Ï Áø´Ü ¹æ½ÄÀ» º¯È­½Ã۱â À§ÇØ ´Ù¾çÇÑ Àü·«À» ÃëÇϰí ÀÖ½À´Ï´Ù. ¾×ü »ý°Ë, Â÷¼¼´ë ¿°±â¼­¿­ ºÐ¼®, AI ±â¹Ý ¾Ë°í¸®Áò°ú °°Àº ±â¼ú ¹ßÀüÀ¸·Î ÇÑ ¹øÀÇ °Ë»ç·Î ´Ù¾çÇÑ ¾ÏÀ» °¨ÁöÇÒ ¼ö ÀÖ´Â Á¤È®µµ°¡ ³ô¾ÆÁö°í ÀÖ½À´Ï´Ù. ±â¾÷µéÀº ÀÌ·¯ÇÑ ±â¹ýÀÇ ½Å·Ú¼º°ú Á¤È®¼ºÀ» ÀÔÁõÇϱâ À§ÇØ ´ë±Ô¸ð ÀÓ»ó½ÃÇèÀ» ¿ì¼±¼øÀ§¿¡ µÎ°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ, »ý¸í°øÇÐ ±â¾÷, ¿¬±¸±â°ü, ÀÇ·á ¼­ºñ½º Á¦°ø¾÷ü °£ÀÇ Àü·«Àû Á¦ÈÞ¸¦ ÅëÇØ Çõ½ÅÀûÀÎ ´ÙÁß ¾Ï °ËÁø µµ±¸ÀÇ °³¹ß ¹× »ó¿ëÈ­°¡ ÃËÁøµÇ°í ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ °Ë»ç´Â ±ÔÁ¦ Áؼö, ºñ¿ë È¿À²¼º ¹× Á¢±Ù¼º¿¡ ÁßÁ¡À» µÎ°í ÀÖÀ¸¸ç, ȯÀÚ °á°ú¸¦ °³¼±Çϱâ À§ÇØ ´õ ºü¸£°í Á¤È®ÇÑ Áø´ÜÀ» Á¦°øÇÔÀ¸·Î½á ¾Ï ¹ß°ß¿¡ Çõ¸íÀ» ÀÏÀ¸ÄÑ ½ÃÀå ¼ºÀåÀ» ´õ¿í ÃËÁøÇϰí ÀÖ½À´Ï´Ù.

¸ñÂ÷

Á¦1Àå ´ÙÁß ¾Ï Á¶±â ¹ß°ß(MCED) ½ÃÀå ½ÃÀå °³¿ä

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå ´ÙÁß ¾Ï Á¶±â ¹ß°ß(MCED) ½ÃÀå ÁÖ¿ä ½ÃÀå µ¿Çâ

Á¦4Àå ´ÙÁß ¾Ï Á¶±â ¹ß°ß(MCED) ½ÃÀå »ê¾÷ Á¶»ç

Á¦5Àå ´ÙÁß ¾Ï Á¶±â ¹ß°ß(MCED) ½ÃÀå ½ÃÀå : COVID-19ÀÇ ¿µÇ⠺м®

Á¦6Àå ´ÙÁß ¾Ï Á¶±â ¹ß°ß(MCED) ½ÃÀå ½ÃÀå ±¸µµ

Á¦7Àå ´ÙÁß ¾Ï Á¶±â ¹ß°ß(MCED) ½ÃÀå ½ÃÀå - Á¦Ç° À¯Çüº°

Á¦8Àå ´ÙÁß ¾Ï Á¶±â ¹ß°ß(MCED) ½ÃÀå ½ÃÀå - ±â¼úº°

Á¦9Àå ´ÙÁß ¾Ï Á¶±â ¹ß°ß(MCED) ½ÃÀå ½ÃÀå - ÃÖÁ¾»ç¿ëÀÚº°

Á¦10Àå ´ÙÁß ¾Ï Á¶±â ¹ß°ß(MCED) ½ÃÀå ½ÃÀå - Áö¿ªº°

Á¦11Àå ÁÖ¿ä º¥´õ ºÐ¼® - ´ÙÁß ¾Ï Á¶±â ¹ß°ß(MCED) ½ÃÀå »ê¾÷

Á¦12Àå ¾Ö³Î¸®½ºÆ®ÀÇ Àü¹æÀ§ Àü¸Á

LSH
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

REPORT HIGHLIGHT

Multi-Cancer Early Detection Market size was valued at USD 880 Million in 2022, expanding at a CAGR of 16.2% from 2023 to 2030.

Multi-cancer early detection (MCED) pertains to the advancement and deployment of technologies and methodologies aimed at identifying various cancer types at their initial stages or even before symptoms manifest, utilizing either a single test or a series of tests. Rather than concentrating solely on a particular cancer type, MCED strives to simultaneously detect multiple cancer types or employ a unified assay. These strategies often involve scrutinizing various biomarkers present in bodily fluids like blood, urine, or saliva, such as circulating tumor DNA (ctDNA), proteins, and other molecular indicators. Technological advancements like next-generation sequencing (NGS), liquid biopsy, and machine learning algorithms play a pivotal role in discerning minute cancer-specific signals, enabling the identification of cancers at earlier, more treatable phases.

Multi-Cancer Early Detection Market- Market Dynamics

Escalating incidence of cancer and governments' heightened emphasis on early cancer detection to propel market demand

The market for multi-cancer early detection (MCED) is poised for growth owing to various factors, including the escalating incidence of cancer and governments' heightened emphasis on early cancer detection. According to the World Health Organization (WHO) in 2020, cancer ranked as the leading cause of global mortality, accounting for nearly 10 million deaths, or approximately one in six deaths. Factors such as smoking, high body mass index, alcohol consumption, obesity, and elevated cholesterol levels contribute to approximately one-third of cancer-related fatalities. The market presents a significant opportunity amid increasing awareness concerning the importance of early cancer detection, aiming to enhance patient survival rates and mitigate treatment expenses. The demand for efficacious early-stage cancer detection methods, facilitating streamlined disease management and subsequently reducing mortality rates, propels the overall market growth.

Multi-Cancer Early Detection Market- Key Insights

As per the analysis shared by our research analyst, the global market is estimated to grow annually at a CAGR of around 16.2% over the forecast period (2023-2030)

Based on product type segmentation, gene panel, LDT and others was predicted to show maximum market share in the year 2022

Based on end user segmentation, hospital was the leading type in 2022

On the basis of region, North America was the leading revenue generator in 2022

Multi-Cancer Early Detection Market- Segmentation Analysis:

The Global Multi-Cancer Early Detection Market is segmented on the basis of Product Type, Technology, End User, and Region.

The market is divided into two categories based on product type: liquid biopsy and gene panel, LDT and others. In 2022, the gene panel, LDT, and other segments captured the largest portion of revenue, primarily due to their provision of testing for multiple types of cancers. Gene panels specifically target the identification of hereditary cancers, and the increasing awareness surrounding hereditary cancers is driving the demand for genetic tests that can detect cancers at their early stages, thereby enhancing patients' survival rates.

The market is divided into three categories based on End User: Hospitals, Diagnostic Laboratories and Others. The hospitals segment emerged as the dominant force in the overall market by securing a significant revenue share in 2022. This dominance is credited to the presence of specialized medical practitioners and healthcare professionals engaged in the diagnosis and treatment of various conditions. Hospitals function as platforms for educating and raising awareness among individuals about specific diseases and disorders. As multi-cancer early detection (MCED) represents an emerging technology with limited awareness among the target audience, hospitals play a crucial role. They facilitate the testing of asymptomatic patients for multiple cancer types, simplifying subsequent treatment procedures.

Multi-Cancer Early Detection Market- Geographical Insights

Geographically, this market is widespread into the regions of North America, Latin America, Europe, Asia Pacific, and the Middle East and Africa. These regions are further divided as per the nations bringing business.

Multi-Cancer Early Detection Market- Competitive Landscape:

The multi-cancer early detection market is undergoing various strategies to transform cancer diagnosis methodologies. Technological advancements in liquid biopsy, next-generation sequencing, and AI-driven algorithms enhance the precision of detecting diverse cancers through a single test. Companies prioritize extensive clinical trials to authenticate the reliability and accuracy of these methodologies. Additionally, strategic collaborations between biotech firms, research institutions, and healthcare providers facilitate the development and commercialization of innovative multi-cancer screening tools. The focus on regulatory compliance, cost-effectiveness, and accessibility of these tests further propels market growth, aiming to revolutionize cancer detection by delivering more prompt and precise diagnoses for improved patient outcomes.

Recent Developments:

In July 2022, Grail, LLC announced the completion of enrollment for the NHS-Galleri trial in under 10 months. This trial involved the enrollment of 140,000 healthy volunteers, marking the largest-ever investigation of a multi-cancer early detection test.

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL MULTI-CANCER EARLY DETECTION MARKET KEY PLAYERS

GLOBAL MULTI-CANCER EARLY DETECTION MARKET, BY PRODUCT TYPE

GLOBAL MULTI-CANCER EARLY DETECTION MARKET, BY TECHNOLOGY

GLOBAL MULTI-CANCER EARLY DETECTION MARKET, BY END USER

GLOBAL MULTI-CANCER EARLY DETECTION MARKET, BY REGION

Table of Contents

1. Multi-Cancer Early Detection Market Overview

2. Executive Summary

3. Multi-Cancer Early Detection Key Market Trends

4. Multi-Cancer Early Detection Industry Study

5. Multi-Cancer Early Detection Market: COVID-19 Impact Analysis

6. Multi-Cancer Early Detection Market Landscape

7. Multi-Cancer Early Detection Market - By Product Type

8. Multi-Cancer Early Detection Market - By Technology

9. Multi-Cancer Early Detection Market - By End User

10. Multi-Cancer Early Detection Market- By Geography

11. Key Vendor Analysis- Multi-Cancer Early Detection Industry

12. 360 Degree Analyst View

13. Appendix

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â